Development of a novel production platform for complex recombinant biotherapeutic

开发复杂重组生物治疗的新型生产平台

基本信息

  • 批准号:
    8251701
  • 负责人:
  • 金额:
    $ 29.63万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-08-01 至 2014-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The manufacturing of recombinant protein-based biopharmaceuticals is a complex, labor and capital intensive endeavor. It currently is accepted that the use of mammalian cells is a requirement for the production of most human proteins, which typically contain extensive post-translational modifications that are not performed by prokaryotes and single-celled eukaryotes. Although mammalian cells such as Chinese hamster ovary cells and baby hamster kidney cells can faithfully biosynthesize most human proteins, the efficiency is dramatically lower than is achieved by bacterial or yeast cells. Of the recombinant proteins currently marketed, coagulation factor VIII is manufactured with the lowest efficiency and is by far the most expensive on a per unit mass basis. Other expensive and difficult to manufacture biopharmaceuticals include the other coagulation factors (e.g. factors IX and VIIa), interferon, and hormone-based cytokines. The goal of the current application is to develop a technology that can improve the production volume and pharmacy price of these difficult to manufacture recombinant biologics. Expression Therapeutics has developed a new baby hamster kidney-derived (BHK) cell line, designated BHK-MS, which can be cultured and expanded indefinitely in serum and blood product-free medium under suspension bioreactor conditions. In the current studies, we are 1) developing and validating the suspension adapted BHK-MS cell line for superior coagulation factor VIII and factor IX production, and 2) performing a pilot-scale manufacturing run and analyzing the biochemical and pharmaceutical characteristics of BHK-MS biosynthesized recombinant factor VIII and factor IX, which will serve as a model, difficult to manufacture biopharmaceuticals. PUBLIC HEALTH RELEVANCE: The long-term commercial objective of the current project is to commercialize a suspension cell-based biomanufacturing platform designed for improved volumetric productivity of complex, hard to manufacture biologics. Low-yield manufacturing processes currently in place often result in limited product availability and high-product costs. Expression Therapeutics has developed a patent-pending cell line designed for efficient manufacturing of recombinant biologics. The studies proposed herein are designed to provide proof-of-concept of the efficiency and scalability, as well as, rigorous preclinical validation and characterization of this novel manufacturing platform.
描述(由申请人提供):基于重组蛋白的生物药物的生产是一项复杂的劳动力和资本密集型奋进。目前公认的是,使用哺乳动物细胞是生产大多数人蛋白质的必要条件,所述人蛋白质通常含有原核生物和单细胞真核生物不进行的广泛的翻译后修饰。虽然哺乳动物细胞,如中国仓鼠卵巢细胞和幼仓鼠肾细胞可以忠实地生物合成大多数人类蛋白质,但效率明显低于细菌或酵母细胞。在目前市售的重组蛋白质中,凝血因子VIII的生产效率最低,并且在单位质量基础上是迄今为止最昂贵的。其他昂贵且难以制造的生物药物包括其他凝血因子(例如因子IX和VIIa)、干扰素和基于细胞因子的细胞因子。本申请的目的是开发一种技术,该技术可以提高这些难以制造的重组生物制剂的产量和制药价格。Expression Therapeutics开发了一种新的幼仓鼠肾衍生(BHK)细胞系,命名为BHK-MS,可在悬浮生物反应器条件下在无血清和血液制品培养基中无限培养和扩增。在目前的研究中,我们1)开发和验证悬浮适应的BHK-MS细胞系,用于生产上级凝血因子VIII和因子IX,2)进行中试规模生产运行,并分析BHK-MS生物合成的重组因子VIII和因子IX的生化和药物特征,其将作为难以生产生物药物的模型。 公共卫生关系:目前项目的长期商业目标是将基于悬浮细胞的生物制造平台商业化,该平台旨在提高复杂、难以制造的生物制品的体积生产率。目前的低产量制造工艺往往导致有限的产品可用性和高产品成本。Expression Therapeutics开发了一种正在申请专利的细胞系,旨在有效生产重组生物制剂。本文提出的研究旨在提供效率和可扩展性的概念验证,以及这种新型制造平台的严格临床前验证和表征。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Gabriela Denning其他文献

Gabriela Denning的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Gabriela Denning', 18)}}的其他基金

Bioengineered Recombinant FVIII
生物工程重组 FVIII
  • 批准号:
    8796739
  • 财政年份:
    2013
  • 资助金额:
    $ 29.63万
  • 项目类别:
Bioengineered Recombinant FVIII
生物工程重组 FVIII
  • 批准号:
    8647463
  • 财政年份:
    2013
  • 资助金额:
    $ 29.63万
  • 项目类别:
Manufacturing Process Development for Bioengineered FVIII
生物工程 FVIII 的制造工艺开发
  • 批准号:
    8454386
  • 财政年份:
    2013
  • 资助金额:
    $ 29.63万
  • 项目类别:
Bioengineered factor VIII gene therapy for hemophilia A
针对血友病 A 的生物工程因子 VIII 基因治疗
  • 批准号:
    8313425
  • 财政年份:
    2012
  • 资助金额:
    $ 29.63万
  • 项目类别:
Clinical Testing of the First Suspension BHK-M Cell Platform Derived Biotherapeutic
第一个悬浮 BHK-M 细胞平台衍生的生物治疗药物的临床测试
  • 批准号:
    9759962
  • 财政年份:
    2012
  • 资助金额:
    $ 29.63万
  • 项目类别:
Bioengineered factor VIII gene therapy for hemophilia A
针对血友病 A 的生物工程因子 VIII 基因治疗
  • 批准号:
    8714274
  • 财政年份:
    2012
  • 资助金额:
    $ 29.63万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 29.63万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 29.63万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.63万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.63万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 29.63万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.63万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 29.63万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 29.63万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 29.63万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.63万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了